{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:08:54Z","timestamp":1793149734232,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYGD22009"],"award-info":[{"award-number":["ZYGD22009"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159302"],"award-info":[{"award-number":["92159302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022ZDZX001"],"award-info":[{"award-number":["2022ZDZX001"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.111936","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T17:55:08Z","timestamp":1712253308000},"page":"111936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses"],"prefix":"10.1016","volume":"132","author":[{"given":"Haoyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.111936_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10027","key":"10.1016\/j.intimp.2024.111936_b0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.111936_b0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"10.1016\/j.intimp.2024.111936_b0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.intimp.2024.111936_b0035","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.intimp.2024.111936_b0040","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0045","first-page":"93","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3","volume":"18","author":"Zhou","year":"2023","journal-title":"Open-Label, Randomized Controlled Trial, J Thorac Oncol"},{"issue":"Pt B","key":"10.1016\/j.intimp.2024.111936_b0050","article-title":"Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"124","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cam4.4940","article-title":"A comprehensive analysis of Glasgow prognostic score (GPS)\/the modified Glasgow prognostic score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.intimp.2024.111936_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.823087","article-title":"Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"9","author":"Ni","year":"2022","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.intimp.2024.111936_b0070","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13643-019-1252-9","article-title":"Preferred reporting items for overviews of reviews (PRIOR): a protocol for development of a reporting guideline for overviews of reviews of healthcare interventions","volume":"8","author":"Pollock","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.intimp.2024.111936_b0080","doi-asserted-by":"crossref","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2024.111936_b0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.intimp.2024.111936_b0090","first-page":"383","article-title":"GRADE guidelines: 1","volume":"64","author":"Guyatt","year":"2011","journal-title":"Introduction-GRADE Evidence Profiles and Summary of Findings Tables, J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.intimp.2024.111936_b0095","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.intimp.2024.111936_b0100","doi-asserted-by":"crossref","first-page":"e071609","DOI":"10.1136\/bmj-2022-071609","article-title":"Dietary sugar consumption and health: umbrella review","volume":"381","author":"Huang","year":"2023","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.intimp.2024.111936_b0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.intimp.2024.111936_b0110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/kjm2.12694","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"39","author":"Li","year":"2023","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.intimp.2024.111936_b0115","doi-asserted-by":"crossref","first-page":"1070019","DOI":"10.3389\/fonc.2023.1070019","article-title":"Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.intimp.2024.111936_b0120","doi-asserted-by":"crossref","first-page":"1234142","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2024.111936_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors: a pooled analysis of 44 retrospective sudies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.intimp.2024.111936_b0130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hed.26997","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: meta-analysis","volume":"44","author":"Takenaka","year":"2022","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CJI.0000000000000392","article-title":"The prognostic significance of baseline neutrophil-to-lymphocyte ratio in melanoma patients receiving immunotherapy","volume":"45","author":"Li","year":"2022","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.intimp.2024.111936_b0140","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s12094-021-02579-9","article-title":"Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)","volume":"23","author":"Liu","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"10.1016\/j.intimp.2024.111936_b0145","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1159\/000526141","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: a systemic review and meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.intimp.2024.111936_b0150","doi-asserted-by":"crossref","first-page":"e28617","DOI":"10.1097\/MD.0000000000028617","article-title":"The relationship between NLR\/PLR\/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"34","key":"10.1016\/j.intimp.2024.111936_b0155","doi-asserted-by":"crossref","first-page":"e21718","DOI":"10.1097\/MD.0000000000021718","article-title":"The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1\/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: a meta-analysis","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2024.111936_b0160","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic Biomarker for patients with metastatic renal cell Carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2024.111936_b0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/imt-2021-0207","article-title":"Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis","volume":"14","author":"Yanagisawa","year":"2022","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10147-021-02061-0","article-title":"Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis","volume":"27","author":"Yanagisawa","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2024.111936_b0175","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.intimp.2024.111936_b0180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.intimp.2024.111936_b0185","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.intimp.2024.111936_b0190","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3389\/fonc.2020.01466","article-title":"Prognostic Biomarkers for pancreatic ductal Adenocarcinoma: an Umbrella review","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.intimp.2024.111936_b0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/0284186X.2021.1886323","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses","volume":"60","author":"Mjaess","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.intimp.2024.111936_b0200","article-title":"Inexpensive systemic inflammatory Biomarkers in Ovarian cancer: an Umbrella systematic review of 17 prognostic meta-analyses, front","volume":"11","author":"El Bairi","year":"2021","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2024.111936_b0205","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cllc.2018.04.008","article-title":"Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 Axis inhibitors in patients with advanced non-small-cell lung cancer","volume":"19","author":"Zer","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2024.111936_b0210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.intimp.2024.111936_b0215","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220011","article-title":"Neutrophil phenotypes and functions in cancer: a consensus statement","volume":"219","author":"Quail","year":"2022","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.intimp.2024.111936_b0220","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/gutjnl-2021-326070","article-title":"Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment","volume":"72","author":"Wang","year":"2023","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.intimp.2024.111936_b0225","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","article-title":"Neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7938","key":"10.1016\/j.intimp.2024.111936_b0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2024.111936_b0235","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.intimp.2024.111936_b0240","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2024.111936_b0245","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2024.111936_b0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.111936_b0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2024.111936_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2024.111936_b0265","article-title":"The relationship between systemic immune inflammatory index and prognosis of patients with non-small cell lung cancer: a meta-analysis and systematic review","volume":"9","author":"Huang","year":"2022","journal-title":"Front Surg"},{"issue":"2","key":"10.1016\/j.intimp.2024.111936_b0270","doi-asserted-by":"crossref","first-page":"344","DOI":"10.21037\/jgo-20-252","article-title":"Prognostic value of systemic immune-inflammatory index in survival outcome in gastric cancer: a meta-analysis","volume":"12","author":"Fu","year":"2021","journal-title":"J Gastrointest Oncol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924004545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924004545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:01:31Z","timestamp":1719979291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924004545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":54,"alternative-id":["S1567576924004545"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111936","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111936"}}